Sponsors
Introduced March 3, 2025 by Frank Pallone · Last progress March 3, 2025
The bill expands transparency, access to care, and public‑health preparedness—potentially lowering drug costs and improving emergency readiness—at the cost of sizable new federal spending, broad reporting and compliance obligations that disproportionately burden smaller providers and plans, privacy risks from detailed data disclosures, and some regulatory uncertainty that could spur litigation or disrupt existing markets.
Patients and plan participants gain much greater visibility into drug pricing, PBM fees, rebates, and claims‑level flows because plans, PBMs, and issuers must produce standardized, machine‑readable reports and participants can request claim‑level difference amounts.
Medicare, Medicaid, and other beneficiaries will have expanded access to care (telehealth flexibilities extended, cross‑state Medicaid enrollment streamlined for children, Acute Hospital Care at Home extended, home infusion Part B coverage added) improving convenience and continuity of care.
Hospitals, community providers, and public health systems receive increased, multi‑year funding and planning (medical countermeasures, regional biocontainment labs, testing preparedness, surge capacity) to strengthen emergency preparedness and domestic manufacturing/supply response.
Millions of patients, plan sponsors, employers, providers, PBMs, and pharmacies face substantial new compliance, reporting, and audit requirements (frequent machine‑readable reports, remittance timelines, PBM/plan disclosures) that will raise administrative costs and may be passed on as higher premiums, narrower networks, or higher prices.
Expanded federal programs, appropriations, and new offices (NTIA spectrum funding, medical countermeasures, grants for public health and pharmacy programs, recycling grants) increase federal spending that may require offsets, create future budget pressures, or crowd out other priorities borne by taxpayers.
Patients and beneficiaries face privacy risks because extensive claims‑level and manufacturer/copay assistance data reporting increases the surface for mishandled or inadequately de‑identified data despite HIPAA references, potentially exposing sensitive health information.
Based on analysis of 37 sections of legislative text.
Imposes consumer-safety rules, mandates PBM transparency and reporting, updates Medicare/Medicaid access and payment rules, advances tech/telecom and public-health preparedness, and directs multiple federal studies.
Creates a wide-ranging package of consumer safety, health care, public-health, technology, and transparency rules. It bans high-concentration sodium nitrite in consumer products, requires adoption of certain electrical safety standards for e-bikes and personal mobility devices, directs EPA to inventory recycling and composting infrastructure, and sets up a Commerce-led blockchain advisory body. Imposes extensive transparency and reporting requirements on pharmacy benefit managers (PBMs) and related entities (for group health plans and ERISA plans), changes Medicare and Medicaid rules (including telehealth coding, home infusion coverage, streamlined enrollment for out-of‑state providers for children, and hospital DSH payment rules), funds and schedules studies and reports (GAO, MedPAC), strengthens public-health emergency countermeasures planning and funding, and expands pediatric/Down syndrome research activities at NIH. Many requirements include deadlines for agency rulemaking and civil monetary penalties for noncompliance.